REFERENCES

REFERENCES
1.
Molyneux
EM
,
Rochford
R
,
Griffin
B
, et al
.
Burkitt’s lymphoma
.
Lancet
.
2012
;
379
(
9822
):
1234
-
1244
.
2.
Pagano
L
,
Caira
M
,
Valentini
CG
,
Fianchi
L
.
Clinical aspects and therapy of sporadic burkitt lymphoma
.
Mediterr J Hematol Infect Dis
.
2009
;
1
(
2
):
e2009030
.
3.
Egan
G
,
Goldman
S
,
Alexander
S
.
Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies
.
Br J Haematol
.
2019
;
185
(
6
):
1071
-
1085
.
4.
Minard-Colin
V
,
Auperin
A
,
Pillon
M
, et al
.
Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen [abstract]
.
J Clin Oncol
.
2016
;
34
(
15
). Abstract 10507.
5.
Cairo
M
,
Auperin
A
,
Perkins
SL
, et al
.
Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group
.
Br J Haematol
.
2018
;
182
(
6
):
859
-
869
.
6.
Porter
DL
,
Levine
BL
,
Kalos
M
,
Bagg
A
,
June
CH
.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
.
N Engl J Med
.
2011
;
365
(
8
):
725
-
733
.
7.
Maude
SL
,
Frey
N
,
Shaw
PA
, et al
.
Chimeric antigen receptor T cells for sustained remissions in leukemia
.
N Engl J Med
.
2014
;
371
(
16
):
1507
-
1517
.
8.
Neelapu
SS
,
Locke
FL
,
Bartlett
NL
, et al
.
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
.
N Engl J Med
.
2017
;
377
(
26
):
2531
-
2544
.
9.
Schuster
SJ
,
Svoboda
J
,
Chong
EA
, et al
.
Chimeric antigen receptor T cells in refractory B-cell lymphomas
.
N Engl J Med
.
2017
;
377
(
26
):
2545
-
2554
.
10.
Avigdor
A
,
Shouval
R
,
Jacoby
E
, et al
.
CAR T cells induce a complete response in refractory Burkitt lymphoma
.
Bone Marrow Transplant
.
2018
;
53
(
12
):
1583
-
1585
.
11.
Rivers
J
,
Annesley
C
,
Summers
C
, et al
.
Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells [abstract]
.
Blood
.
2018
;
132
(
suppl 1
). Abstract
2957
.
12.
Cheson
BD
,
Pfistner
B
,
Juweid
ME
, et al;
International Harmonization Project on Lymphoma
.
Revised response criteria for malignant lymphoma
.
J Clin Oncol
.
2007
;
25
(
5
):
579
-
586
.
13.
Pan
J
,
Yang
JF
,
Deng
BP
, et al
.
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
.
Leukemia
.
2017
;
31
(
12
):
2587
-
2593
.
14.
Pan
J
,
Niu
Q
,
Deng
B
, et al
.
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
.
Leukemia
.
2019
;
33
(
12
):
2854
-
2866
.
15.
Lee
DW
,
Gardner
R
,
Porter
DL
, et al
.
Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048]
.
Blood
.
2014
;
124
(
2
):
188
-
195
.
16.
Neelapu
SS
,
Tummala
S
,
Kebriaei
P
, et al
.
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
.
Nat Rev Clin Oncol
.
2018
;
15
(
1
):
47
-
62
.
17.
Yang
ZZ
,
Grote
DM
,
Ziesmer
SC
, et al
.
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma
.
Blood
.
2011
;
118
(
10
):
2809
-
2820
.
18.
Shah
NN
,
Maatman
T
,
Hari
P
,
Johnson
B
.
Multi targeted CAR-T cell therapies for B-cell malignancies
.
Front Oncol
.
2019
;
9
:
146
.
This content is only available as a PDF.
You do not currently have access to this content.